Status:
UNKNOWN
Autophagy and Venous Endothelial Function
Lead Sponsor:
Neuromed IRCCS
Collaborating Sponsors:
Principal investigator: Giacomo Frati
Co-investigator: Francesco Pompeo
Conditions:
Venous Disease
Eligibility:
All Genders
18-85 years
Brief Summary
The molecular mechanisms involved in venous endothelial dysfunction are largely unknowns. Autophagy is an intracellular mechanism devoted to the removal of damaged cytoplasmic elements. Previous evide...
Detailed Description
Endothelial dysfunction contributes to different cardiovascular diseases, such as atherosclerosis, myocardial infarction, stroke and peripheral artery diseases. Recent evidence also demonstrated that ...
Eligibility Criteria
Inclusion
- Eligible subjects undergoing saphenectomy
- Patients with chronic venous insufficiency
- Patients with varicose veins
- Eligible subjects undergoing peripheral artery revascularization through implantation of venous by-pass derived from saphenous vein
- Acceptance and signature of the informed consent
Exclusion
- Chronic and acute Inflammatory diseases
- Immunological and rheumatic diseases
- Pre-existing or ongoing neoplasms
- Infectious diseases
- Previous organ transplantation
- Treatment with pharmacological therapies able to modulate autophagy, i. e. rapamycin and derivative compounds (rapalogues).
- Antioxidant therapies in the last three months
- Patients with surgical technical complications
Key Trial Info
Start Date :
February 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 1 2023
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04138134
Start Date
February 1 2022
End Date
April 1 2023
Last Update
February 8 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
IRCCS Neuromed
Pozzilli, Isernia, Italy